Russian medical community uses new immunotherapy to develop cancer vaccine

experts at the Institute of Organic Chemistry of the Russian Academy of Sciences are currently working on a new cancer vaccine that "activates" the body's immune system to produce a strong immune response to cancer cellsAccording to the latest issue of the Russian Academy of Sciences Report, the Russian medical community believes that the body's immune system is very "tolerant" of cancer cellsThe immune system "ignores" the cancerous process of cells and fails to produce an effective anti-cancer immune response to stimulate immune cells to recognize and remove cancer cellsTherefore, finding substances that stimulate a strong immune response is criticalExperts have found that the neurocortic sin GM3 has such a functionThe vaccine developed by Russian experts is based on neurocoryginlipid GM3Neuroscoine lipids are an integral part of human and mammalian cell membranes, with various effects, including neurokines GM3 can produce a large number of melanomas, stomach cancer cells and othertumorscellsThe study found that the use of neurotic glycosine GM3 alone was not effective in stimulating a strong immune responseTo further improve the effectiveness of the vaccine, the researchers also added hemoglobin extracted from mollusc blood to synthesize a new type of antigen with a special molecular structureTests have shown that the immune system can be "activated" by a vaccine containing new artificial antigens to produce antibodiesOnce the antibody encounters malignanttumorantigen, a specific binding occurs, and the macrophages and lymphocytes in the antibody can be activated to destroy the cancer cells